CompletedNCT03818256
Miricorilant for Weight Gain Linked to Antipsychotic Medication
About this title
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
Read the official source —Medication studyAges 18–65United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Bentonville and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 4, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 71
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03818256
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)
Get this study by email
Recruitment & locations
CompletedBentonville · Little Rock · Culver City
23 more locations
- Garden Grove
- Lemon Grove
- Oakland
- Oceanside
- Rancho Cucamonga
- Miami
- North Miami
- Okeechobee
- Chicago
- Lincolnwood
- Wichita
- Glen Burnie
- Las Vegas
- New York
- Raleigh
- Dayton
- Thorndale
- West Chester
- DeSoto
- Houston
- Richardson
- Salt Lake City
- Bellevue
Questions about this study
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Miricorilant and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
